UCB SA (UCBJF)
| Previous close | 126.05 |
| Open | 126.05 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 126.05 - 126.05 |
| 52-week range | 69.70 - 126.05 |
| Volume | |
| Avg. volume | 91 |
| Market cap | 24.065B |
| Beta (5Y monthly) | 0.40 |
| PE ratio (TTM) | 67.41 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 1.47 (1.17%) |
| Ex-dividend date | 26 Apr 2024 |
| 1y target est | N/A |
- PR Newswire
UCB presents new data highlighting developments across expansive neurology portfolio at 76th American Academy of Neurology (AAN) Annual Meeting
UCB (Euronext Brussels: UCB), a global biopharmaceutical company, today announced the latest research from its expansive neurology portfolio and pipeline to be presented at the 76th American Academy of Neurology (AAN) Annual Meeting, April 13-18, 2024, in Denver, Colorado, USA.
- PR Newswire
UCB Launches Make HStory, an Educational Campaign Offering Resources and Support for Those Living with Hidradenitis Suppurativa
UCB, a global biopharmaceutical company, today announced the launch of Make HStory, an educational campaign that provides tools and resources for those living with hidradenitis suppurativa (HS) and their dermatologists.
- PR Newswire
FDA Accepts Supplemental Biologics License Applications for BIMZELX® (bimekizumab-bkzx) for Moderate-to-Severe Hidradenitis Suppurativa and Additional 2mL Device Presentations
UCB, a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for BIMZELX® (bimekizumab-bkzx), an IL-17A and IL-17F inhibitor, for the treatment of adults with moderate-to-severe hidradenitis suppurativa (HS). In addition, a second sBLA for the BIMZELX 2mL device presentations has also been accepted.
